AXSM Q4 2023 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72M+193.5% YoY

Gross Profit

$64M89.7% margin

Operating Income

-$98M-137.4% margin

Net Income

-$99M-137.9% margin

EPS (Diluted)

$-2.08

QoQ Revenue Growth

+23.8%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$588M

Total Liabilities

$397M

Stockholders' Equity

$191M

Cash & Equivalents

$386M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72M	$24M	+193.5%
Gross Profit	$64M	$22M	+190.5%
Operating Income	-$98M	-$60M	-64.0%
Net Income	-$99M	-$61M	-61.1%

Revenue Segments

Product

$71M99%

Royalty

$783,0001%